Stockreport
Biotech Analysis Central Pharma News: Johnson & Johnson's Partnership, Dynavax's Advancements, Aveo's Positive Results [Seeking Alpha]
Last johnson & johnson earnings: 4/16 06:40 am
Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF
Summary Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Johnson & Johnson Acquires Rights To A Drug That Treats Rare Forms Of Cancer News: Recently, Johnson & Johnson ( JNJ ) announced that it had created a partnership deal with a Korean biotech named Yuhan ( OTCPK:YUHNF ) . The reason for creating this deal is so that JNJ could get its hands on Yuhan's 3rd generation EGFR tyrosine-kinase inhibitor known as lazertinib. In order to obtain such a deal, JNJ only had to pay an upfront payment of $50 million to Yuhan. If clinical trials proceed accordingly, then Yuhan could also receive up to $1.205 billion in potential milestone payments as well. JNJ will also have to give the biotech tiered double-digit royalty payments for net sales made on any products sold. Analysis: I think this is a good deal for JNJ for a few reasons. The first reason is that it gets to work on the dru
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | JNJ | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
JNJ alerts
JNJ alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
NEWS
NEWS
- New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early[PR Newswire]
- Best Practices From Vanguard's Innovation Studio [Forbes][Forbes]
- INSIGHT-Modi’s jobs deficit: J&J’s largest India plant idle 3 years after completion [Reuters (UK)][Reuters]
- 6 Things Johnson & Johnson Wants You to Know About Its Pharmaceuticals [The Motley Fool][The Motley Fool]
- J&J recalls certain surgical staplers due to potential failure [Seeking Alpha][Seeking Alpha]
- More
JNJ
SEC Filings
SEC Filings
- 5/1/19 - Form 10-Q
- 4/26/19 - Form 3
- 4/26/19 - Form 8-K
- JNJ's page on the SEC website
- More